Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | UGCG | Q16739 | 5/20 | 0.50 |
| ▸ | GBA2 | Q9HCG7 | 5/20 | 0.50 |
| ▸ | GBA1 | P04062 | 4/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.43 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.43 |
| ▸ | LCT | P09848 | 2/20 | 0.43 |
| ▸ | SI | P14410 | 2/20 | 0.43 |
| ▸ | MGAM | O43451 | 1/20 | 0.43 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.42 |
| ▸ | NAAA | Q02083 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL518615 | 1.00 | L3MBTL1 (0.54) | L3MBTL1TDP1TSHRUGCGGBA2 | |
| SCHEMBL1246210 | 1.00 | L3MBTL1 (0.54) | L3MBTL1TDP1TSHRUGCGGBA2 | |
| SCHEMBL8482826 | 1.00 | L3MBTL1 (0.54) | L3MBTL1TDP1TSHRUGCGGBA2 | |
| SCHEMBL6212152 | 1.00 | L3MBTL1 (0.54) | L3MBTL1TDP1TSHRUGCGGBA2 | |
| SCHEMBL96809 | 1.00 | L3MBTL1 (0.54) | L3MBTL1TDP1TSHRUGCGGBA2 | |
| SCHEMBL9684333 | 1.00 | L3MBTL1 (0.54) | L3MBTL1TDP1TSHRUGCGGBA2 | |
| SCHEMBL25208054 | 1.00 | L3MBTL1 (0.54) | L3MBTL1TDP1TSHRUGCGGBA2 | |
| SCHEMBL814418 | 1.00 | L3MBTL1 (0.54) | L3MBTL1TDP1TSHRUGCGGBA2 | |
| SCHEMBL1007794 | 1.00 | L3MBTL1 (0.54) | L3MBTL1TDP1TSHRUGCGGBA2 | |
| SCHEMBL22906771 | 0.98 | L3MBTL1 (0.53) | L3MBTL1TDP1TSHRUGCGGBA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 455 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115028680-B | PROTAC compound for targeted degradation of Cyclophilin A and preparation method and application thereof | 深圳湾实验室 | 2023-01-20 | — | — | CN | claimed |
| CN-115028680-A | PROTAC compound for targeted degradation of Cyclophilin A and preparation method and application thereof | 深圳湾实验室 | 2022-09-09 | — | — | CN | claimed |
| US-6989052-B1 | Phase change ink printing process | XEROX CORPORATION (US) | 2006-01-24 | — | — | US | claimed |
| US-20060004123-A1 | PHASE CHANGE INK PRINTING PROCESS | XEROX CORPORATION | 2006-01-05 | — | — | US | claimed |
| EP-4743465-A1 | BICYCLIC MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2026-05-20 | — | — | EP | disclosed |
| US-12594339-B2 | Lipid prodrugs of JAK inhibitors and uses thereof | SEAPORT THERAPEUTICS, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| EP-4712974-A2 | STAT DEGRADERS AND USES THEREOF | Recludix Pharma, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4709370-A2 | STAT DEGRADERS AND USES THEREOF | Recludix Pharma, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12569464-B2 | Protein-protein interaction inducing technology | ARVINAS OPERATIONS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-12559486-B2 | Tau-protein targeting compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| EP-3681875-B1 | CYCLIC PEPTIDE ANTIBIOTICS | HOFFMANN LA ROCHE (CH) | 2026-01-14 | — | — | EP | disclosed |
| US-12448323-B2 | Dental glass composition | KURARAY NORITAKE DENTAL INC. (JP) | 2025-10-21 | — | — | US | disclosed |
| US-5488140-A | ANTICONVULSANTS | CIBA-GEIGY CORPORATION (US) | 1996-01-30 | — | — | US | disclosed |
| US-5294734-A | 1-phosphato-4-amino-pent-2-enoic acids and derivatives | CIBA-GEIGY CORP. (US) | 1994-03-15 | — | — | US | disclosed |
| US-5155113-A | Administering 5-fluorouracil and derivatives with pyridine and pyridone derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-10-13 | — | — | US | disclosed |
| US-5145865-A | Fatty acid, cholesterol synthesis inhibitors; enzyme inhibitors; antilipemic agents | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1992-09-08 | — | — | US | disclosed |
| EP-0180188-B1 | A COMPOSITION FOR INCREASING THE ANTI-CANCER ACTIVITY OF AN ANTI-CANCER COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-04-15 | — | — | EP | disclosed |
| US-5081287-A | Pesticidal polyhalo alkenoic acid esters | FMC CORPORATION (US) | 1992-01-14 | — | — | US | disclosed |
| EP-0393607-A2 | Phenylcarboxylic acid derivatives having a hetero ring | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1990-10-24 | — | — | EP | disclosed |
| EP-0180188-A2 | A composition for increasing the anti-cancer activity of an anti-cancer compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12569464-B2 | Protein-protein interaction inducing technology | STUB1, MDM2, XIAP | L3MBTL1 198/4885TDP1 2247/4885TSHR 2796/4885 |
| US-12559486-B2 | Tau-protein targeting compounds and associated methods of use | UBQLN2, UBQLN1, CRBN | L3MBTL1 539/4885TDP1 1778/4885TSHR 2915/4885 |
| US-12594339-B2 | Lipid prodrugs of JAK inhibitors and uses thereof | JAK1, JAK3, JAK2 | L3MBTL1 2032/4885TDP1 1878/4885TSHR 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.